Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving?
Restricted accessReview articleFirst published online September, 2017
Clinical Development and Commercialization of Advanced Therapy Medicinal Products in the European Union: How Are the Product Pipeline and Regulatory Framework Evolving?
The research and development of advanced therapy medicinal products (ATMPs) has been active in Europe and worldwide during recent years. Yet, the number of licensed products remains low. The main expected legal change in the near future in the European Union (EU) concerns the regulation on clinical trials (536/2014), which will come into force in 2018. With this new framework, a more harmonized and swift process for approval of clinical trials is anticipated, which is expected to support the entry of new innovations into the EU market. A survey on ATMPs in clinical trials during 2010–2015 in the EU was conducted in order to study the trends of ATMP development since the earlier survey published in 2012. According to the results, the number of clinical trials using ATMPs is slowly increasing in the EU. Yet, the focus is still in early development, and the projects are mainly carried out by small and medium-sized enterprises, academia, and hospitals. Oncology is the main area of clinical development. Yet, the balance between cell-based products and gene therapy medicinal products in this area may be changing in the future due to the new T-cell technologies. Many limitations and challenges are identified for ATMP development, requiring proportionate regulatory requirements. On the other hand, for such a novel field, the developers should be active in considering possible constraints and actively engage with authorities to look for solutions. This article provides up to-date information on forthcoming regulatory improvements and discusses the main challenges hampering the commercialization of ATMPs in the EU.
Regulation (EC) No. 1394/2007 of the European Parliament and of the Council on Advanced Therapy Medicinal Products and amending Directive 2001/83/EC and Regulation (EC) No. 726/2004. OJ L, 2007; 324:121–137.
RaperSE, ChirmuleN, LeeFS, et al.Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab, 2003; 80:148–158.
7.
CavazzanaM, SixE, Lagresle-PeyrouC, et al.Gene therapy for X-linked severe combined immunodeficiency: where do we stand?. Hum Gene Ther, 2016; 27:108–116.
8.
Le BlancK, SamuelssonH, GustafssonB, et al.Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia, 2007; 21:1733–1738.
MaciulaitisR, D'ApoteL, BuchananA, et al.Clinical development of advanced therapy medicinal products in Europe: evidence that regulators must be proactive. Mol Ther, 2012; 20:479–482
11.
BissonI, GreenE, SharpeM, et al.Landscape of current and emerging cell therapy clinical trials in the UK: current status, comparison to global trends and future perspectives. Regen Med, 2015; 10:169–179.
Directive 2001/20/EC of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. OJ L, 2001;121/34.
21.
Regulation 536/2014 of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC. OJ L, 2014;158/1.
Commission Directive 2001/18/EC on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC. OJ L, 2001; 106:1–38.
GardnerJ, FaulknerA, MahalatchimyA, et al.Are there specific translational challenges in regenerative medicine? Lessons from other fields. Regen Med, 2015; 10:885–895.
37.
European Commission.. Report from the Commission to the European Parliament and the Council in accordance with Article 25 of Regulation (EC) No 1394/2007 of the European Parliament and of the Council on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. http://ec.europa.eu/health/files/advtherapies/2014_atmp/atmp_en.pdf (last accessed June5, 2017).
TafuriG, PagniniM, MoseleyJ, et al.How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice. Br J Clin Pharmacol, 2016; 82:965–973.
